Amanda Darekar

1.4k citations

29 papers · 1.1k indexed · h-index 16

Impact in

Urology top 1%
- Urinary Bladder and Prostate Research
Endocrinology, Diabetes and Metabolism top 2%
- Diabetes Treatment and Management

Papers in

Urology 14
- Urinary Bladder and Prostate Research 14
Rheumatology 13
- Pelvic floor disorders treatments 13

Co-authors: Steven G. Terra Brett Lauring Juan P. Frías Didier Saur Adrian Wagg Susan Huyck Caty Ebel Bitoun Feng Guo
Journals: Diabetes Obesity and Metabolism (5 papers)Neurourology and Urodynamics (4 papers)The Journal of Urology (4 papers)Contemporary Clinical Trials (2 papers)Journal of Pediatric Urology (2 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

Amanda Darekar

28 papers receiving 1.1k citations

Peers

Countries citing papers authored by Amanda Darekar

Since Specialization

Citations

This map shows the geographic impact of Amanda Darekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Darekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Darekar more than expected).

Fields of papers citing papers by Amanda Darekar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda Darekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Darekar. The network helps show where Amanda Darekar may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Amanda Darekar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amanda Darekar Line = papers co-authored together Amanda Darekar links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study The Lancet. Gastroenterology & hepatology ·Vincent Wai‐Sun Wong, Neeta B. Amin, Hirokazu Takahashi, Amanda Darekar, Frank Tacke, Ifraha Abbas, Shi Lin, Atsushi Nakajima, Naim Alkhouri, Michael Charlton, Quentin M. Anstee	2025	5
2	Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study BMJ Open ·Neeta B. Amin, Amanda Darekar, Quentin M. Anstee, Vincent Wai‐Sun Wong, Frank Tacke, Manoli Vourvahis, Douglas S. Lee, Michael Charlton, Naim Alkhouri, Atsushi Nakajima, Carla Yunis	2022	40
3	Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study Journal of Pediatric Urology ·Takeya Kitta, Amanda Darekar, Bimal Malhotra, Mohamed H. Shahin, А Сурожский, N Boku, 田村昌士, Alejandra Nieto, Tim Crook	2022	2
4	Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials Cardiovascular Diabetology ·Jie Liu, Annpey Pong, Silvina Gallo, Amanda Darekar, Steven G. Terra	2019	18
5	Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies Diabetes and Vascular Disease Research ·Jie Liu, Lisa Tarasenko, Steven G. Terra, Susan Huyck, 透栗本, Annpey Pong, Roberto A. Calle, Silvina Gallo, Amanda Darekar, James P. Mancuso	2019	22
6	Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone Diabetes Obesity and Metabolism ·Steven G. Terra, Kristen Focht, Melanie J. Davies, Juan P. Frías, Giuseppe Derosa, Amanda Darekar, Gregory T. Golm, Jeremy Johnson, Didier Saur, Brett Lauring, Sam Dagogo‐Jack	2017	117
7	Development of a predictive model for urgency urinary incontinence Contemporary Clinical Trials ·Amanda Darekar, Martin Carlsson, Navid Tabibzadeh, Fady Ntanios, Erin Mangan, Daniel Arumí, David Scholfield	2016	6
8	Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study Neurourology and Urodynamics ·Adrian Wagg, Amanda Darekar, Daniel Arumí, Vik Khullar, Matthias Oelke	2014	9
9	Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry International Urogynecology Journal ·Niels Klarskov, Amanda Darekar, David Scholfield, XING Hui, Gunnar Lose	2013	8
10	Effects of drug cessation after flexible‐dose fesoterodine in patients with overactive bladder British Journal of Urology ·Vik Khullar, Linda Cardozo, Con Kelleher, Timothy L. Hall, John Ryan, Caty Ebel Bitoun, Amanda Darekar, Daniel Arumí, Adrian Wagg	2013	9
11	Evaluation of Cognitive Function in Healthy Older Subjects Treated with Fesoterodine Postgraduate Medicine ·Gary G. Kay, Paul Maruff, David Scholfield, Bimal Malhotra, XING Hui, Amanda Darekar, Zander Brietzke	2012	52
12	Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder Journal of Pediatric Urology ·Bimal Malhotra, Ahmed El‐Tahtawy, Ellen Q. Wang, Amanda Darekar, Freya Oswald, Tim Crook, David Scholfield, Pramod Reddy	2012	20
13	Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation International Urogynecology Journal ·Linda Cardozo, Timothy L. Hall, John Ryan, Caty Ebel Bitoun, 坂田真宏, Amanda Darekar, Adrian Wagg	2012	24
14	Efficacy and Tolerability of Fesoterodine in Older People With Overactive Bladder: Results of the Open-Label Phase of the SOFIA Trial Adrian Wagg, Vik Khullar, Daniela Marschall‐Kehrel, Martin C. Michel, Matthias Oelke, Amanda Darekar, Caty Ebel Bitoun, Ian H. Osterloh, David Weinstein	2011	1
15	Evaluation of Cognitive Function in Healthy Older Adults Treated With Fesoterodine Neurourology and Urodynamics ·Gary G. Kay, Paul Maruff, David Scholfield, Bimal Malhotra, XING Hui, Amanda Darekar, Zander Brietzke	2011	3
16	Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder Neurourology and Urodynamics ·Magdalena Pacwa-Płociniczak, Freya Oswald, Amanda Darekar, Ian Mills	2010	31
17	1508 TANEZUMAB REDUCES PAIN AND URGENCY IN INTERSTITIAL CYSTITIS: RESULTS OF A PHASE 2 TRIAL The Journal of Urology ·Robert J. Evans, Robert Moldwin, Freya Oswald, Amanda Darekar, David Scholfield, Ian Mills	2010	1
18	Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction Drug Metabolism and Disposition ·Odette A. Fahmi, Susan Hurst, David R. Plowchalk, Jack Cook, Feng Guo, Kuresh Youdim, Maurice Dickins, Alex Phipps, Amanda Darekar, Ruth Hyland, R. Scott Obach	2009	167
19	Application of CYP3A4in vitrodata to predict clinical drug–drug interactions; predictions of compounds as objects of interaction British Journal of Clinical Pharmacology ·Kuresh Youdim, Aref Zayed, Maurice Dickins, Alex Phipps, Afra Abdel Halim, Amanda Darekar, Ruth Hyland, Odette A. Fahmi, Susan Hurst, David R. Plowchalk, Jack Cook, Feng Guo, R. Scott Obach	2008	69
20	Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated Phase I study Contemporary Clinical Trials ·Alex Collie, Amanda Darekar, Georges Weissgerber, Melvin Toh, Peter J. Snyder, Paul Maruff, John P. Huggins	2006	68

About Amanda Darekar

Amanda Darekar is a scholar working on Urology, Rheumatology, Gastroenterology, Endocrinology, Diabetes and Metabolism and Pharmacology, having authored 29 papers that have together received 1.1k indexed citations. Recurring topics across this work include Urinary Bladder and Prostate Research (14 papers), Pelvic floor disorders treatments (13 papers), Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (6 papers), Gastroesophageal reflux and treatments (4 papers), Diabetes Management and Research (4 papers), Urinary Tract Infections Management (4 papers) and Analytical Chemistry and Chromatography (2 papers). The work is most often cited by research in Urology (283 citations), Endocrinology, Diabetes and Metabolism (451 citations), Pharmacology (198 citations), Rheumatology (252 citations) and Pharmacology (122 citations). Amanda Darekar has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Steven G. Terra, Brett Lauring, Juan P. Frías, Didier Saur, Adrian Wagg, Susan Huyck, Caty Ebel Bitoun, Feng Guo, Jack Cook and Ruth Hyland. Their work appears in journals such as Diabetes Obesity and Metabolism, Neurourology and Urodynamics, The Journal of Urology, Contemporary Clinical Trials and Journal of Pediatric Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact